Ads by Google
Industry-funded studies of breast cancer therapies are more likely to report positive results than non-pharmaceutical funded studies.
Breast cancer treatment trials supported by the pharmaceutical industry are more likely to report positive results than non-sponsored studies.
Hypothesis suggests they are at higher risk for metastatic growth after surgery.
Women, receiving treatment for early stage breast cancer, may benefit from a supervised group exercise program.
A unique survey of African American breast cancer survivors at heightened risk for hereditary breast cancer has found the majority do not believe they have an increased chance of developing the cancer again.
A large scale analysis of data on breast cancer risk has concluded that a common variation in the gene caspase 8 is associated with a somewhat lower risk of the disease.
For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates.
A test that determines the likelihood of breast cancer returning within five to 10 years after a woman's initial cancer.
Fewer patients die at hospitals that perform more surgeries.
Revealing the role of a gene associated with the propagation of breast cancer in two of five affected women.
Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women.
Greater after care monitoring and screening needed for men with breast cancer.
Estrogen is known to enhance the growth and migration of breast cancer cells.
Radiation therapy after lumpectomy and five years of treatment with the drug tamoxifen can dramatically reduce the risk of both breast cancer recurrence and new tumors in older women with early breast cancer.
Radiotherapy after breast conserving surgery for breast cancer reduces recurrence and prevents development of additional breast tumors in older women with early stage breast disease.
Early termination of breast cancer drug Tamoxifen may negatively affect treatment efficacy.
A new biomarker could lead to earlier detection and better treatment of breast cancer.
Breast cancer cells that lose an important "genetic switch" on their surface are highly likely to spread to other parts of the body.
Lapatinib (Tykerb) should be investigated for use in the earlier treatment of HER2 (ErbB2) positive breast cancer.